Gary Jacob
Chief Executive Officer at OKYO PHARMA LIMITED
Net worth: 67 180 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Brancaccio | M | 76 |
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 20 years |
| Bernard Denoyer | M | 77 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 14 years |
| Willy Simon | M | 72 | 9 years | |
| Keeren Shah | F | 47 | 8 years | |
| Vanila Singh | M | 53 | 4 years | |
| Gabriele Cerrone | M | 52 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 14 years |
| Kaouthar Lbiati | M | 45 | 2 years | |
| John Cavan | M | 65 | 8 years | |
| Timothy Block | M | 69 | 11 years | |
| Michael Dubin | M | 68 | 3 years | |
| Paul Spencer | M | - | 2 years | |
| Raj Patil | M | 66 | 6 years | |
| Daniel Trepanier | M | - | 5 years | |
| Daren Ure | M | - | 5 years | |
| John Bell | M | 71 |
University of Oxford
| 35 years |
| Jules S. Jacob | M | - | 7 years | |
| William Clementi | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hugh Grant | M | 65 | 20 years | |
| Kunwar Shailubhai | M | 67 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 9 years |
| Robert Foster | M | 65 | 7 years | |
| Christopher Chipman | M | 50 | 3 years | |
| Craig C. Talluto | M | - |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 8 years |
| Philip Needleman | M | - |
G.D. Searle LLC
| 4 years |
| Richard Berman | M | 81 | 1 years | |
| Michael Barrow | M | - |
University of Oxford
| 3 years |
| Matt Greenwood | M | - |
University of Oxford
| 3 years |
| Julia Black | F | - |
University of Oxford
| 8 years |
| Kevin L. Thurm | M | 62 |
University of Oxford
| 1 years |
| Daniel Kapi | M | - |
University of Oxford
| 5 years |
| Theresa Matkovits | M | 56 | 3 years | |
| Man Wai Chiu | M | 55 |
University of Oxford
| 5 years |
| Yat Hung Fu | M | 60 |
University of Oxford
| 6 years |
| Ick-Soo Kim | M | 68 |
University of Oxford
| 3 years |
| Peter Wijngaard | M | 61 | 3 years | |
| Duraiswami Narain | M | 60 | 20 years | |
| Doron Junger | M | - |
University of Oxford
| 6 years |
| Robin N. Lowe | M | 59 |
University of Oxford
| 4 years |
| Antony J. Fairbanks | M | - |
University of Oxford
| 3 years |
| James Sapirstein | M | 63 | 4 years | |
| Rupert Charles de Borchgrave d'Altena | M | - |
University of Oxford
| 7 years |
| James Allen | M | 57 |
University of Oxford
| 5 years |
| Judson A. Cooper | M | 65 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Joshua D. Schein | M | 63 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Randall K. Johnson | M | 77 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 8 years |
| Thomas H. Adams | M | 81 | 6 years | |
| Tamar Howson | F | 75 | 2 years | |
| William Guttman | M | 63 |
University of Oxford
| 5 years |
| Arnold Lippa | M | 77 | 8 years | |
| Simon H. Thomas | M | 64 |
University of Oxford
| 5 years |
| Anand Reddi | M | 42 | 2 years | |
| Byron Auguste | M | 56 |
University of Oxford
| 4 years |
| Shirley Cunningham | F | 63 | 15 years | |
| Christopher McGuigan | M | 65 | 3 years | |
| Stephen Swaffield | M | 61 |
University of Oxford
| 6 years |
| Chris Watt | M | - |
University of Oxford
| 4 years |
| Chee Peng Ng | M | 54 |
University of Oxford
| 4 years |
| Jason Bush | M | - |
University of Oxford
| 3 years |
| Douglas Stuart McCallum | M | 58 |
University of Oxford
| 3 years |
| Steven Paul Frederick Ward | M | 53 |
University of Oxford
| 3 years |
| Darren Scott Cockburn | M | 55 |
University of Oxford
| 3 years |
| Jacqui Darbyshire | F | - |
University of Oxford
| 4 years |
| Yu Leng Khor | M | 53 |
University of Oxford
| 4 years |
| Matthew Ridgwell | M | 59 |
University of Oxford
| 4 years |
| Guan Hong Yap | M | 60 |
University of Oxford
| 4 years |
| Duncan Fatkin | M | - |
University of Oxford
| 4 years |
| Ruben Bhagobati | M | - |
University of Oxford
| 3 years |
| Emma Cookson | F | - |
University of Oxford
| 3 years |
| Michael Hewett | M | - |
University of Oxford
| 3 years |
| Ignatius Low | M | - |
University of Oxford
| 4 years |
| Argyris Stasinakis | M | - |
University of Oxford
| 3 years |
| Neill Penney | M | - |
University of Oxford
| 4 years |
| Jih-Shian Yeo | M | 55 |
University of Oxford
| 4 years |
| Mark Richards | M | 58 |
University of Oxford
| 3 years |
| Greg Eckersley | M | 59 |
University of Oxford
| 4 years |
| Richard Webb | M | 58 |
University of Oxford
| 1 years |
| Philippa Aldrich | F | - |
University of Oxford
| 4 years |
| Simon Munton Bullivant | M | - |
University of Oxford
| 4 years |
| Fariba Fischel Ghodsian | M | - |
University of Oxford
| 3 years |
| Gerald Cardinale | M | 56 |
University of Oxford
| 2 years |
| Valerie Monchi | F | - |
University of Oxford
| 4 years |
| Alan Jonathan Dodsworth | M | - |
University of Oxford
| 4 years |
| Charles Philip Cohen | M | 55 |
University of Oxford
| 4 years |
| Jason Matthew Brown | M | 56 |
University of Oxford
| 4 years |
| Michael J. Buchanan | M | - |
University of Oxford
| 4 years |
| Koosum P. Kalyan | F | 68 |
University of Oxford
| 4 years |
| Matthew James Whittell | M | - |
University of Oxford
| 4 years |
| Maria Teresa H. D. S. M. Roque Dal Fabbro | F | - |
University of Oxford
| 3 years |
| Jonathan Hepple | M | 53 |
University of Oxford
| 3 years |
| Matthew James Benson | M | 57 |
University of Oxford
| 4 years |
| Robert Baugh | M | - |
University of Oxford
| 4 years |
| Carolyn Anne Prowse | F | 52 |
University of Oxford
| 4 years |
| Christoph Matthias Widmer | M | 57 |
University of Oxford
| 4 years |
| Mathew Welch | M | 60 |
University of Oxford
| 1 years |
| Joanne Warner | M | 62 |
University of Oxford
| 3 years |
| Eleni D. Dendrinou-Louri | M | 70 |
University of Oxford
| 4 years |
| Yvonne Muthien | M | 67 |
University of Oxford
| 4 years |
| James C. Clarke | M | - |
University of Oxford
| 4 years |
| Andrew Edward Anson | M | 59 |
University of Oxford
| 3 years |
| Mark Jennings | M | 63 |
University of Oxford
| 3 years |
| Brendan Ludden | M | - |
University of Oxford
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 73 | 73.00% |
| United States | 29 | 29.00% |
| Australia | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gary Jacob
- Personal Network